Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
MK-5720 by Merck for Schizophrenia: Likelihood of Approval
MK-5720 is under clinical development by Merck and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs...